The research team emphasized that albumin nanocarriers provide exceptional biocompatibility, reproducible synthesis, and adjustable size characteristics during production while facilitating passive tumor targeting through enhanced permeation and retention (EPR) effects and active targeting via surface modifications with specific ligands. This evidence concerns the gene ALB and neoplasm.